PALO ALTO, Calif.--(BUSINESS WIRE)--Artificial, a lab automation company that is catalyzing the life science digital revolution with its first-of-its-kind orchestration platform, announced the addition of Dr. Yvonne Linney to its Board of Directors and executive leadership team as Chief Operating Officer (COO). Dr. Linney brings more than 30 years’ experience as an executive at industry-leading life sciences and diagnostic companies, including Agilent Technologies and Bayer Diagnostics/Siemens.
In her new role as COO, Yvonne is responsible for spearheading the company’s business development strategy to create and deliver value to customers, partners, and investors. Yvonne continues to serve on the board of Bionano Genomics. Before joining Artificial, she was an executive of Transcriptic, initially as COO and expanding to CEO, where she brokered a multi-year, multi-million dollar agreement between Eli Lilly and Transcriptic (now Strateos). Prior to the role, she was an executive at Agilent Technologies, initially as Vice President and General Manager for the Genomics Business and expanding to Vice President and General Manager of the Life Science Solutions Division. At Agilent, she established a $1.5B Life Science Group by leading their strategy into the Life Science research and Drug Discovery markets.
Prior to joining Agilent in 2006, Yvonne held senior product marketing positions at Bayer Diagnostics (now Siemens Healthcare), and Caliper Life Sciences (now part of Perkin Elmer). From 1993-2003, she was a key member of the senior leadership team at Amersham International (now GE Healthcare), collaborating with the founding members of the Global Human Genome Project. Yvonne holds a BS in Microbiology and Virology from Warwick University, UK, and a PhD in Genetics from Leicester University, UK.
“I’m excited to join Artificial and help drive a long sought after digital revolution in the life science lab so that the benefits of automation are available more broadly,” said Dr. Linney. “Labs today have an urgent need to improve their efficiency and reliability, which I believe Artificial’s orchestration platform will directly address. Their ability to provide a single platform that encompasses all aspects of the lab including the manual tasks carried out by technicians will enable labs to adopt automation sooner. Their platform is also of particular relevance today with COVID-19. If labs had access to Artificial’s software during the pandemic, which allows them to set up their experiments remotely and direct a limited workforce on site, they could have continued on with their operations without sacrificing any productivity.”
David Fuller, CEO of Artificial, said, “We’re very pleased that Yvonne has joined our executive leadership team and Board of Directors to spearhead Artificial’s business development and strategic efforts. Her experience and domain expertise will be paramount to our ability to expand our reach to the market as well as establishing strong partnerships with the life sciences community to maximize the potential and reach of our orchestration platform.”
Artificial empowers every lab to realize the benefits of automation for their next breakthrough by providing a first-of-its-kind software platform that keeps the human-in-the loop. Artificial’s aLab Suite orchestrates everything that happens in a lab, including the manual tasks that still make up much of today’s lab work, to generate robust reliability and reproducibility. By bringing robotics, automation, data, and people together on a single easy-to-use platform, labs are now empowered to go from scientific intent to reliable results faster and more efficiently.
For more information, please visit www.artificial.com.